

---

# CURRICULUM VITAE

**DR CHRISTOPHER U MISSLING**

**DATE OF BIRTH: 28 JULY 1965**

**51 W 52<sup>ND</sup> STREET, 7<sup>TH</sup> FLOOR  
NEW YORK, NY 10019**

**WORK HISTORY:**

**Anavex Life Sciences Corp. (NASDAQ: AVXL), New York, NY (\$200M Biotech Company) 2013 – Present**

***PRESIDENT & CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD***

- Initiated and executed turnaround plan, which resulted in shareholder value increase by more than 2400% (\$480 million), from \$20M to \$500M within 15 months. Raised \$70M in equity from institutional investors. Uplisted from OTC to NASDAQ in 2014. Grew the company staff from 1 to 20 including full time employees and consultants.
- Executed successfully a Phase IIa clinical study in Alzheimer's patients. Awarded research grant by the Michael J. Fox Foundation (MJFF) for Parkinson's research to develop ANAVEX 2-73 for the treatment of Parkinson's. Grant also awarded by Rett syndrome.org for the clinical development of ANAVEX 2-73 in Rett syndrome. Grants for pre-clinical studies also awarded by FRAXA (Fragile X, Autism Spectrum Disorder) and Angelman Foundation (Angelman syndrome).
- Preparation of clinical studies Phase II/III in Alzheimer's disease, Phase II in Parkinson's disease and Phase II in Rett syndrome.

**Brimberg & Co., New York, NY 2007 – 2013**

***HEAD OF HEALTHCARE INVESTMENT BANKING***

- Providing advice on equity raising from institutional and private investors for alternative investment vehicles, including funds, private equity structures and venture capital projects.
- Overseeing the funding process from initial discussion to due diligence and term-sheet negotiation, advising the companies on all transaction issues.

**Apeiron Partners, Boston, MA 2005 – 2007**

***PARTNER, BUSINESS DEVELOPMENT CONSULTANT***

- Create value by identifying and executing business development transactions.
- Executed transactions: on behalf of Isis Pharmaceuticals, licensed Alicaforsen to Atlantic Pharmaceuticals, on behalf of Isis Pharmaceuticals, acted as Business Development Consultant for the licensing of Mipomersen, on behalf of Artisan Pharma, acted as CFO and Business Development VP, on behalf of Alexion Pharmaceuticals, worked on spin-out of AAT, on behalf of Ashai Kasei Medical worked on clinical trial phase 3 analysis for Adacolumn, on behalf of Asilas acted as CEO/CBO for the spin-out from Yale University.
- Created development models and probability analysis tools for long range planning capturing the whole value chain of research and development to market approval.

**ImmunoGen Inc. (NASDAQ: IMGN), Cambridge, MA (\$700M Biotech Company) 2004 – 2005**

***VICE PRESIDENT AND CHIEF FINANCIAL OFFICER***

- Responsible for all financial matters and Investor Relations and Corporate Communications.
- Responsible for financial repositioning of the company to maximize investment flow.

- 
- P&L responsibility for \$10 million G&A budget. Preparation of 10-K's, 10-Q's and other SEC required legal reportings on a timely basis and in full compliance with NASDAQ listing requirement.
  - Provided strategic input, risk analysis and leadership on decision-making issues affecting the organization and in partnership discussions and business development issues.
  - Achieved shareholder value increase by more than 75% (\$160 million), from \$210M to \$370M within 3 months.

**Curis Inc. (NASDAQ: CRIS), Cambridge, MA (\$300M Biotech Company) 2002 – 2004**

***SENIOR VICE PRESIDENT STRATEGIC PLANNING AND CHIEF FINANCIAL OFFICER***

- Initiated and executed turnaround plan, which resulted in shareholder value increase by more than 500% (\$170 million), from \$30M to \$200M within 15 months. Lead a successful PIPE financing transaction of \$10.9M in 8/03; oversaw term negotiations and closing documentation. Represented the company in Business Development discussions and investor road shows. Structured partnership transactions with Johnson & Johnson, Genentech and Wyeth with more than \$500 million in total upfront and milestone payments. Negotiated a favourable \$14 million payment from Stryker in exchange for termination of future royalties of OP-1 sales.
- Achieved superior corporate governance index score (CGQ) of 98.3% vs. average industry score of 94.4%. Oversaw implementation of new legal requirements in response to the Sarbanes-Oxley Act, recent SEC and NASDAQ rule changes.
- Restructured the balance sheet by terminating the JV with Elan, resulting in a cancellation of preferred stock valued \$13 million and reducing the overhang and increasing the transparency of the balance sheet significantly. Cut administrative costs by over 40% and stabilized the yearly expenses from \$10.8M to \$6.0M over one year through restructure and applied fiscal discipline. Achieved average share price performance from \$0.94 in the third quarter 2002 to \$5.13 in the fourth quarter 2003. Built extensive network with equity analysts, investment banks and international institutional investors. Sustained media recognition from the Wall Street Journal, Boston Business Journal, Boston Globe, BioCentury and NECN (TV).

**Aventis SA (incl. Hoechst AG) (NYSE: AVE), Strasbourg, France (\$60B Pharma Company) 1997 – 2001**

***HEAD OF FINANCIAL PLANNING AVENTIS GROUP***

- Involved as key member of the Aventis transaction team in all aspects of the merger including strategic fit and rationale, financial due diligence and final exchange offer negotiation depending on firm value based on DCF analysis. Execution team leader in four corporate transactions: Celanese spin-off and IPO (\$2 billion), HRVet divestment (\$600 million), Vianova Resins disposal (sales of \$400 million), Clariant exchangeable bond (\$2.6 billion).
- Responsible for managing the development of Aventis consolidated budgets and strategic long-term financial plans. Focus on top line growth, EPS increase and free cash flow development as communicated with the investor community. Managed and trained senior analysts in Strategic Planning Process. Provide support to Investor Relations and External Reporting for developing external commitments.
- Key member of the Aventis rating improvement team, resulting in improved rating of A-/ A3 for the Group from Standard & Poor's.
- Coordinated in close dialogue with CFO about interpretation, communication and outlook of quarterly earnings results. Collaborated with CFO on Supervisory Board meetings including preparation of Board presentations. Responsible for sales, operating profit, cash flow and corporate debt forecast of the Group. Compiled monthly reports to the Board of Management and conducted presentations in monthly CFO meetings.

**Deutsche Bank (NYSE: DB) (\$33B Financial Service Company) 1994 – 1997**

**Deutsche Bank, London, UK and Frankfurt, Germany**

***TRAINEE, ANALYST, INVESTMENT BANKING GROUP***

- 
- M&A and Equity Capital Market Advisory.
  - Drafted, processed and presented strategic M&A business opportunities from \$100 million to \$50 billion to international clients. Prepared quantitative analysis including the identification of comparable companies and precedent transactions. Constructed discounted cash flow models and analysed EPS dilution impacts under various deal and leverage scenarios.
  - Analyzed financial accounts in UK-GAAP, US-GAAP, IAS and HGB.
  - Rotation through banking divisions: Project Finance, Asset Management, Trading, Controlling, Export Finance, Credit Risk Control, Private Banking.
- 

## **EDUCATION:**

**MBA from J.L. Kellogg Graduate School of Management** 1998 – 2000  
**Northwestern University and WHU**

International Executive MBA, A grade (top 5%)

Thesis: *Using Real Options in Strategic Pharmaceutical and Biotech Valuation*

**Ludwig-Maximilians-University, Munich** 1991 – 1994

PhD in Bioorganometallic Chemistry (magna cum laude)

**Ludwig-Maximilians-University, Munich** 1986 – 1991

MSc (Diploma) in Chemistry, 1.1 (A grade)

---

## **LANGUAGES:**

- English (fluent), German (native), Italian (native), French (basic to fluent knowledge)
- 

## **EXTRACURRICULAR ACTIVITIES:**

- Skiing, marathons and music